ISIS Pharmaceuticals, Inc.

• Is RNA Drug Development Coming of Age?

  By Terry Chrisomalis - April 11, 2013 | Tickers: ALNY, ISIS, SRPT

  Of late, it seems that good things are happening with RNA drug companies. There are a few biotech stocks that are advancing their pipelines in the RNA field, and breakthroughs in RNA will lead to a huge boost for these drug companies. On Oct. 2, 2006, Dr. Craig Mello and his colleague Andrew Fire were awarded the Nobel Prize for their discovery of RNA interference. 

  It has been a long more »

• Is RNA Drug Development Coming Of Age?

  By Terry Chrisomalis - April 8, 2013 | Tickers: ALNY, ISIS, SRPT

  Lately it seems good things are happening with RNA drug companies. There are a few biotech stocks that are advancing their pipelines in the RNA field, and breakthroughs in RNA will lead to a huge boost for these drug companies. On October 2, 2006 Dr. Craig Mello, and his colleague Andrew Fire were awarded the Nobel Prize for their discovery of RNA interference. 

  It has been a long road for more »

• Three Stocks For The Long Haul

  By Declan Fallon - March 6, 2013 | Tickers: ATVI, ALNY, ISIS, NTES, THC

  I have reviewed over 80 stocks as investment opportunities. Some were more successful than others; for example, Tesoro Corporation (best performer) gained 99% within a sector that has underperformed the broader market, but Penn Virginia Corp (worst performer) dropped 33% and is unlikely to recover from the share dilution that cut the price. Collectively, 65% of the stocks I have featured have gained, with an average return of 6.6 more »

• Better Cancer Treatment: Partnerships and Dividends

  By Josef Ray Dagatan - January 17, 2013 | Tickers: AEGR, AZN, ISIS

  The quality of life that we live is determined in part by how healthy our physical being is. All of us get sick at one time or another, for which we consult a doctor who prescribes a medicine that helps us to regain our health. But as we all know, sicknesses such as cancer and other autoimmune diseases cannot be cured by over-the-counter drugs. Drugs for these kinds of ailments more »

• Understanding Volume Trends

  By Declan Fallon - December 20, 2012 | Tickers: AVG, ISIS, POT

  In a brief departure from normal service, I will talk a little about what I like to see in a healthy stock, besides strong fundamentals.  Everyone wants to own a stock which is rising, and to be out - or selling - a stock which is declining.  However, stepping into the unknown is always a risk, but sometimes there are markers which can give an indication of things to come.

  Besides a more »

• Five Stocks Hit Hard by Sellers, But Two Still Offer Something for Buyers

  By Declan Fallon - November 28, 2012 | Tickers: CHK, ISIS, MELI, NTES, SPLK

  It has been just over a month since my last review.  In that post I featured stocks which were existing holdings of mine.  For the record, I added to these positions in November as I took advantage of the 9% drop in the S&P.  Under my investing thesis, the market hadn't reached the level I like to see to add new positions, but that is not to say more »

• A Biotechnology Firm Making Its First Step Towards Profitability?

  By Declan Fallon - September 18, 2012 | Tickers: BIIB, ISIS

  As bullish markets expand, monies are channelled not just into established names, but to companies which offer the potential to become the next big names. In recent weeks, the number of stocks which have seen money flows above their typical average have markedly increased.  Of these movers-and-shakers, one to make the grade was ISIS Pharmaceuticals (NASDAQ: ISIS).

  ISIS Pharmaceuticals researches and develops antisense drugs, used for the treatment of cardiovascular more »

• Excellent Science + Unmet Need Equal Great Returns

  By Streetwise Reports - May 21, 2012 | Tickers: CRIS, GHDX, ISIS, MAKO, NXTM

  By George S. Mack, The Life Sciences Report

  Short-term gains come with pipeline products in mid-stage development.

  It is satisfying on those rare occasions when I get a straight answer to my first question in an interview for The Life Sciences Report. "Our theme is to focus on the markets with the most profit potential," answers Chief Investment Strategist Alex Daley of Casey's Extraordinary Technology. Daley has had some more »